Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Home›Research›Companies

Companies

Loading
Home›
Research›
Companies›
PostEra
AddedMar 20, 2024
UpdatedJul 3, 2026
PostEra

PostEra

Series B

PostEra: ML-driven drug discovery, advancing medicinal chemistry with top biopharma partnerships.

HQ
Boston, MA, US
Founded
2019
Accelerator
Y Combinator logoY CombinatorW20
Overview
Compare
Fundraising
Employees
News
Website

PostEra, founded with the mission to revolutionize medicinal chemistry through machine learning, aims to accelerate drug discovery and bring more cures to patients. The company leverages advanced AI technologies to streamline the Design-Make-Test cycle in medicinal chemistry. PostEra offers services that include advancing small molecule programs through partnerships with biopharma companies and developing its own internal drug pipeline. Their market focus spans collaborations with major pharmaceutical companies and research institutions.

Notable figures associated with PostEra include Aaron Morris. The company has raised $26 million from top investors and secured $1 billion in AI partnerships, including multi-year agreements with industry giants like Amgen, Pfizer, and the NIH. PostEra also spearheaded the world's largest open-science drug discovery initiative. These achievements underscore PostEra's significant impact on the biopharma industry, positioning it as a leader in AI-driven drug discovery.

PostEra - Similar Companies

Insitro logo

Insitro

insitro.com

Numerion Labs logo

Numerion Labs

numerionlabs.ai

Pathos AI logo

Pathos AI

pathos.com

Model Medicines logo

Model Medicines

modelmedicines.com

1910 logo

1910

1910genetics.com

DeepCure logo

DeepCure

deepcure.ai

Elucidata logo

Elucidata

elucidata.io

Biosim logo

Biosim

Owkin logo

Owkin

owkin.com

Terray Therapeutics logo

Terray Therapeutics

terraytx.com

Zephyr AI logo

Zephyr AI

zephyrai.bio

Persist AI logo

Persist AI

persist-ai.com

Superluminal Medicines logo

Superluminal Medicines

superluminalrx.com

Cognaisent logo

Cognaisent

cognaisent.com

Ordaos logo

Ordaos

ordaos.bio

PostEra - Quick Facts

Who are PostEra's competitors?

Companies similar to PostEra include Insitro, Numerion Labs, Pathos AI and Model Medicines.

When was PostEra founded?

PostEra was founded in 2019.

Where is PostEra's headquarters located?

PostEra's headquarters is located in Boston, MA, US.

How much has PostEra raised to-date?

As of May 18, 2022, PostEra has raised a total of $26.3M (USD).

How many employees does PostEra have?

PostEra has 34 employees as of Mar 29, 2024.

PostEra - Classification

Ownership
  • Private Equity
  • Venture Capital
Technology
  • AI
  • Machine Learning
Geographic Exposure
  • Global
Model
  • Platform
Revenue
  • Recurring
  • Software
Customer
  • Enterprise
Main Product
  • Drug Discovery
Tags
  • AI Operations
  • Biotech
  • Consulting
NAICS
  • 540000Professional, Scientific, and Technical Services
  • 541500Computer Systems Design and Related Services
  • 541000Professional, Scientific, and Technical Services
  • 541510Computer Systems Design and Related Services
  • 541511Custom Computer Programming Services
SIC
  • 7300Business Services
  • 7370Computer Programming, Data Processing, And Other Computer Related
  • 7371Computer Programming Services
Show 8 more industry codes
NAICS
  • 513200Software Publishers
  • 518000Computing Infrastructure Providers, Data Processing, Web Hosting, and Related Services
  • 518200Computing Infrastructure Providers, Data Processing, Web Hosting, and Related Services
  • 510000Information
  • 513000Publishing Industries
  • 513210Software Publishers
  • 518210Computing Infrastructure Providers, Data Processing, Web Hosting, and Related Services
SIC
  • 7372Prepackaged Software